2018-05-10T16:38:40-05:00 2017-12-31 341874260 CBIZ MHM LLC 700 WEST 47TH STREET SUITE 1100 KANSAS CITY MO 64112 990 2017-01-01 431889037 KANSAS CITY AREA LIFE SCIENCES INSTITUTE INC KANS 8167537700 30 W PERSHING ROAD NO 210 KANSAS CITY MO 64108 WAYNE O CARTER PRESIDENT 8167537700 2018-05-09 1 LISA BURKE P00220718 8169455500 2017 2022-09-23 18:48:47Z WAYNE O CARTER 30 W PERSHING ROAD NO 210 KANSAS CITY MO 64108 1703232 0 X WWW.KCLIFESCIENCES.ORG X 2000 MO THE PURPOSE OF THIS ORGANIZATION IS TO PROMOTE AND FOSTER DEVELOPMENT OF LIFE SCIENCES IN THE KANSAS CITY METROPOLITAN AREA AND TO PROVIDE A PLATFORM FOR DEVELOPMENT AND COOPERATION IN THE AREA OF LIFE SCIENCES IN THE KANSAS CITY METROPOLITAN AREA. 11 10 6 36 0 0 1724324 1603349 104363 90800 900 9083 0 0 1829587 1703232 349863 616772 0 0 677307 697292 0 0 56372 343347 400834 1370517 1714898 459070 -11666 2014840 2003174 0 0 2014840 2003174 X THE PURPOSE OF THIS ORGANIZATION IS TO PROMOTE AND FOSTER DEVELOPMENT OF LIFE SCIENCES IN THE KANSAS CITY METROPOLITAN AREA AND TO PROVIDE A PLATFORM FOR DEVELOPMENT AND COOPERATION IN THE AREA OF LIFE SCIENCES IN THE KANSAS CITY METROPOLITAN AREA. 0 0 1435206 616772 90800 SEE SCHEDULE O 1435206 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 8 0 6 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 X 11 10 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X X SHARON NEWMAN 8167537700 30 W PERSHING ROAD STE 210 KANSAS CITY MO 64108 WILLIAM S BERKLEY DIRECTOR (CHAIR) 0.50 X X 0 0 0 DONALD CRAIG BRATER DIRECTOR 0.10 X 0 0 0 WAYNE O CARTER PRESIDENT 40.00 X X 256994 0 36421 DAVID FRANTZE DIRECTOR 0.20 X 0 0 0 IRVINE O HOCKADAY JR DIRECTOR 0.30 X 0 0 0 ROBERT A KIPP DIRECTOR (VICE CHAIRMAN) 0.00 X X 0 0 0 STEPHEN REINTJES DIRECTOR (SECRETARY AND TREASURER) 0.25 X X 0 0 0 THOMAS SACK PHD DIRECTOR 0.30 X 0 0 0 ANNE D ST PETER DIRECTOR 0.30 X 0 0 0 STEVEN ST PETER MD DIRECTOR 0.30 X 0 0 0 DEBORAH WILKERSON DIRECTOR 0.30 X 0 0 0 KEITH A GARY VICE PRESIDENT 40.00 X 160160 0 25935 417154 0 62356 2 0 1 0 0 1603349 1603349 LIFE SCIENCES DINNER 900099 49100 49100 ONE HEALTH SYMPOSIUM 900099 24290 24290 BIOINFORMATICS CONFERE 900099 17410 17410 90800 9083 9083 1703232 90800 0 9083 616772 616772 479511 341043 104508 33960 150046 129651 7454 12941 36052 2503 33549 31683 22740 6462 2481 29645 11445 18200 37104 36073 1029 2 13317 5799 6097 1421 22363 10653 11704 6 42885 25731 12777 4377 16982 16982 8188 7984 204 5203 5203 ANNUAL MTG & LIFE SCI. 96141 96141 0 0 CONSULTANTS 58536 57208 1328 0 BIOINFORMATICS EVENT 16208 16208 0 0 MEMBERSHIPS AND DUES 13687 10445 3242 0 40575 27828 11563 1184 1714898 1435206 223320 56372 24249 0 1975333 1990906 127915 115647 15258 12268 2014840 2003174 0 0 X 1583840 1568760 431000 434414 2014840 2003174 2014840 2003174 -11666 0 X 0 1 X 1 0 X X X 1 GREATER KC COMM FNDTN 431152398 8 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 2211 2211 1435206 1437417 218742 54686 0 0 181272 231410 178496 218742 809920 1214880 1716 1707 2594 2211 8228 45318 57853 44624 54686 202481 303722 52126 40751 11375 75789 74896 893 12268 X 1703232 0 1703232 0 1703232 1714898 0 1714898 0 1714898 PART X, LINE 2: KANSAS CITY AREA LIFE SCIENCES INSTITUTE, INC. HAS BEEN GRANTED AN EXEMPTION FROM INCOME TAXES BY THE INTERNAL REVENUE SERVICE UNDER THE PROVISIONS OF SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THERE WAS NO UNRELATED BUSINESS INCOME DURING 2017 OR 2016. THE INSTITUTE HAS EVALUATED THE STANDARDS REQUIRING DISCLOSURE OF UNCERTAIN TAX POSITIONS UNDER FASB ASC 740, INCOME TAXES, AND DETERMINED THAT THERE ARE NO MATERIAL MATTERS WHICH REQUIRE DISCLOSURE. 1 UNIVERSITY OF MISSOURI 115 BUSINESS LOOP 70W MIZZOU NH RM 501 COLUBMIA MO 65211 436003859 170(B)(1)(A)(II) 149891 KCALSI 17-4 COLLABORATE2CURE AWARD GUAUNFU LI; KCALSI 17-5 PATTON TRUST GRANT MONIQUE LORSON; KCALSI 17-11 NEXUS GRANT NATHAN SKELLEY CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY MO 64108 440605373 501(C)(3) 196560 KCALSI 17-2 BLUE KC DR. COLVIN; KCALSI 17-3 BLUE KC DR. GOLDMAN; KCALSI 17-7 PATTON TRUST RESEARCH GRANT: SARAH SODEN; KCALSI 17-6 PATTON TRUST RESEARCH GRANT: TARAK SRIVASTAVA KU MEDICAL CENTER RESEARCH INSTITUTE INC 3901 RAINBOW BLVD KANSAS CITY KS 66160 481108830 501(C)(3) 50000 KCALSI 17-1 BLUE KC OUTCOMES STEVEN SIMPSON UNIVERSITY OF KANSAS CENTER FOR RESEARCH 2385 IRVING HILL ROAD LAWRENCE KS 66045 480680117 501(C)(3) 50000 KCALSI 17-9 NEXUS GRANT WENDY PICKING KANSAS STATE UNIVERSITY 102 ANDERSON HALL MANHATTAN KS 66506 480771751 170(B)(1)(A)(II) 99964 KCALSI 17-12 NEXUS GRANT RICHARD TODD; KCALSI 17-13 NEXUS GRANT MAJID JABERI-DOURAKI, PHD KANSAS CITY UNIVERSITY 1750 INDEPENDENCE AVE KASNAS CITY MO 64106 440545280 501(C)(3) 48888 KCALSI 17-8 COLLABORATE2CURE AWARD BAKI AGBAS 4 2 PART I, LINE 2: GRANTS ARE FOR A ONE YEAR DURATION. GRANT RECIPIENTS AGREE TO PROVIDE A PROGRESS REPORT AT SIX MONTHS AND A SUMMARY TECHNICAL PROGRESS REPORT WITHIN 30 DAYS OF THE END OF THE PERFORMANCE TO INCLUDE: 1. A BRIEF SUMMARY OF TECHNICAL PROGRESS RELATIVE TO THE GOALS AND OBJECTIVES PROPOSED IN THE PROPOSAL. 2. A BRIEF STATEMENT CONCERNING THE EFFECTIVENESS AND BENEFITS REALIZED FROM THE COLLABORATIONS INVOLVED. GRANT RECIPIENTS AGREE TO PROVIDE (UPON REQUEST) A COPY OF ALL PROPOSALS SUBMITTED TO EXTERNAL FUNDING AGENCIES AS A RESULT OF THE SUPPORT PROVIDED AND SUBSEQUENTLY NOTIFY KCALSI OF ACCEPTANCE OR REJECTION THEREOF. IF THE GRANT RECIPIENT RECEIVES ALTERNATIVE FUNDS FOR SUPPORT OF THIS SPECIFIC PROJECT, KCALSI REQUESTS THAT THE RECIPIENT RETURN ANY UNEXPENDED FUNDS TO THE INSTITUTE SO THAT THEY CAN BE USED TO SUPPORT OTHER INVESTIGATORS. X X X 0 0 0 0 0 0 0 0 0 WAYNE O CARTER PRESIDENT 256994 0 0 0 0 0 27000 0 9421 0 293415 0 0 0 KEITH A GARY VICE PRESIDENT 160160 0 0 0 0 0 16785 0 9150 0 186095 0 0 0 FORM 990, PART III, LINE 4A 2017 ACCOMPLISHMENTS: 1. REGIONAL LIFE SCIENCES STRATEGIC ASSESSMENT-"PATH TO 2025" THE KANSAS CITY AREA LIFE SCIENCES INSTITUTE (KCALSI) ENGAGED DELOITTE TO EXECUTE A STRATEGIC ASSESSMENT OF THE REGIONAL LIFE SCIENCES IN 2015. THE PROCESS UTILIZED THE "COLLECTIVE IMPACT" MODEL FROM STANFORD UNIVERSITY AND WAS LED BY AN EXPERIENCED STEERING COMMITTEE COMPRISED OF COMMUNITY AND BUSINESS LEADERS IN THE LIFE SCIENCES. THE COMMITTEE LOOKED AT BOTH DRIVERS OF CLUSTER ENHANCEMENT AND REGIONAL SCIENTIFIC STRENGTHS. THE REGIONAL VISION DEVELOPED THROUGH THE ASSESSMENT PROCESS STATES, "THE KANSAS CITY REGION IS A GLOBAL LEADER AT THE NEXUS OF HUMAN AND ANIMAL HEALTH BENEFITING ALL OUR CITIZENS AND THE ECONOMY." THESE NEXUS OPPORTUNITIES WILL BE DIFFERENT FOR EACH STRATEGIC AREA AND WILL LIKELY RANGE FROM USING NATURALLY OCCURRING CANCER IN DOGS FOR ACCELERATING HUMAN DISCOVERIES TO ADVANCING OUR STRENGTH IN HEALTH IT AND OUTCOMES RESEARCH. FOUR AREAS OF SCIENTIFIC STRENGTH WERE IDENTIFIED: ANIMAL HEALTH, CANCER RESEARCH AND CARE, NEUROSCIENCE, AND HEALTH IT AND OUTCOMES RESEARCH. ADDITIONALLY, FOUR DRIVERS OF CLUSTER ENHANCEMENT WERE IDENTIFIED: COLLABORATION, WORKFORCE DEVELOPMENT, CAPITAL FORMATION, AND MESSAGING AND MARKETING. TASK FORCES WERE CREATED FOR EACH CLUSTER DRIVER AND WORK GROUPS FOR EACH SCIENTIFIC AREA. THE WORK OF THESE GROUPS WILL BE CRITICAL FOR THE SUCCESS OF OUR ENTIRE ECOSYSTEM AND ENABLE US TO BE MORE GLOBALLY COMPETITIVE. FY2017 PROGRESS IMPLEMENTATION OF THE "PATH TO 2025" IS DESCRIBED BELOW. WHILE ALL WORKING GROUPS WERE RECOGNIZING POWERFUL SYNERGIES WITHIN THE STRATEGY AND EXPLORING OPPORTUNITIES, TWO SIGNIFICANT THEMES FRAMED MOST OF OUR ACTIVITIES THROUGHOUT 2017: -THE NEXUS OF HUMAN AND ANIMAL HEALTH -OUTCOMES RESEARCH AND HEALTH IT THE NEXUS OF HUMAN AND ANIMAL HEALTH: THE NEXUS OF HUMAN AND ANIMAL HEALTH IS AN OPPORTUNITY TO ADVANCE HUMAN AND ANIMAL HEALTH BY BRINGING THESE SECTORS TOGETHER AND LOOKING FOR OVERLAP AND SYNERGY. EXAMPLES OF HUMAN/ANIMAL HEALTH NEXUS OPPORTUNITIES PURSUED IN 2017 INCLUDE: -REGIONAL COMPARATIVE ONCOLOGY PROGRAM. ONLY 11% OF CANCER DRUGS EFFECTIVE IN MICE HAVE BEEN APPROVED FOR TREATMENT IN PEOPLE. MEANWHILE, VETERINARIANS HAVE USED HUMAN CHEMOTHERAPEUTICS AS OFF-LABEL CANCER TREATMENTS FOR DOGS AND CATS FOR DECADES NOTING SIMILAR EFFICACY AND SIDE EFFECTS AS IN HUMANS ACROSS A RANGE OF TUMOR TYPES. THE CANCER RESEARCH AND CARE WORKING GROUP, LED BY DR. ROY JENSEN, BEGAN PLANS TO ACCELERATE CANCER THERAPEUTICS FOR PEOPLE AND PETS. THE REGIONAL COMPARATIVE ONCOLOGY PROGRAM IS AIMED AT FACILITATING TRANSLATIONAL CANCER DRUG DEVELOPMENT ACROSS THE NEXUS OF HUMAN AND ANIMAL MEDICINE. ONE EFFORT BEING PLANNED IS A VETERINARY ONCOLOGIST WITH CONCURRENT APPOINTMENTS IN THE REGIONAL VETERINARY SCHOOLS AND HUMAN CANCER CENTERS WOULD FACILITATE CLINICAL RESEARCH IN CLIENT-OWNED DOGS AND CATS WITH CANCER AS A TOOL TO SPEED UP HUMAN "PROOF OF CONCEPT" DRUG RESEARCH. -AS A DIRECT OUTCOME OF THE COLLABORATE2CURE SERIES ON CANCER IMMUNOTHERAPY, A CLINICAL PARTNERSHIP WAS DEVELOPED BETWEEN CHILDREN'S MERCY AND ELIAS ANIMAL HEALTH/TVAX BIOMEDICAL TO IMPACT PEDIATRIC ONCOLOGY. BIOLOGY OF PEDIATRIC OSTEOSARCOMA (BONE CANCER) AND CANINE OSTEOSARCOMA ARE VERY SIMILAR AND GENE EXPRESSION IS VIRTUALLY IDENTICAL BETWEEN CHILDREN AND DOGS. THIS PEDIATRIC ONCOLOGY PROGRAM WILL ENHANCE THE VALUE OF THIS TRANSLATIONAL OPPORTUNITY. -THE ANIMAL HEALTH WORKING GROUP IDENTIFIED A GAP AND A TREMENDOUS OPPORTUNITY FOR THE REGION. LED BY DR. RALPH RICHARDSON, K-STATE OLATHE CEO, AND DARYL PINT, CEVA CEO, THE GROUP RECOGNIZED THAT ANIMAL HEALTH RESEARCHERS LACKED A COMPREHENSIVE INTEROPERABLE DATABASE. THEY BEGAN DEVELOPING A PLAN LINKING ANIMAL HEALTH AND HUMAN HEALTH DATA VIA THE CERNER FHIR PLATFORM. NAMED "1DATA", THIS TRANSLATIONAL DATABASE PROVIDES A PLATFORM FOR MINING SHARED DATA FROM MANY SOURCES INCLUDING PHARMACEUTICAL DEVELOPMENT FOR PEOPLE AND ANIMALS, CLINICAL RECORDS, PROTEIN INTERACTIONS, GENOMIC AND ENVIRONMENTAL DATA. THE PROJECT IS LED BY DR. JERRY WYCKOFF, UNIVERSITY OF MISSOURI-KANSAS CITY (UMKC) PROFESSOR, AND DR. JIM RIVIERA, K-STATE PROFESSOR EMERITUS. THE OPPORTUNITIES WITHIN THE DATABASE ARE LIMITLESS. AMONG THEM IS THE GOAL TO SYSTEMATICALLY CHANGE THE REGULATORY PROCESS BY USING BIOLOGICAL MODELING AND SIMULATIONS TO ACCELERATE DRUG APPROVALS; ACCELERATE DEVELOPMENT OF HUMAN AND ANIMAL THERAPEUTICS AND DIAGNOSTICS; AND TO TRAIN STUDENTS IN BIOINFORMATICS, MODELING AND ANALYTICAL METHODS. THE 1DATA PLATFORM CAN BE USED BY RESEARCHERS, INDUSTRY, HEALTH PROVIDERS, AND COMMUNITY ORGANIZATIONS TO IMPACT THE DRUGS AND TECHNOLOGY AVAILABLE TO HELP SAVE LIVES AND IMPROVE THE QUALITY OF LIFE FOR HUMANS AND ANIMALS. -KCALSI BEGAN DEVELOPING THE NEXUS PROOF OF CONCEPT (POC) FUND AIMED AT ACCELERATING PHARMACEUTICAL DEVELOPMENT FOR HUMANS BY USING ANIMALS WITH NATURALLY OCCURRING DISEASE. HISTORICALLY, HUMAN HEALTH RESEARCHERS AND VETERINARY RESEARCHERS HAVE WORKED IN SILOS. THE PHARMACEUTICAL JUSTIFICATION FOR THE SEPARATION WAS PRESUMED REGULATORY HURDLES. AS OUR DISEASE UNDERSTANDING ADVANCES, MORE PEOPLE ARE APPRECIATING THE OPPORTUNITY AT THE NEXUS RATHER THAN THE HURDLES. THE FUND WILL PROVIDE PROOF OF CONCEPT FUNDING TO ADVANCE NOVEL TECHNOLOGIES TO MARKET THROUGH STUDIES NECESSARY TO DE-RISK THEM AND ATTRACT INVESTORS. TECHNOLOGY CONCEPTS WILL BE SOURCED FROM ENTREPRENEURS, UNIVERSITIES AND FROM INDUSTRY WHERE CONCEPT VALIDATION IS NEEDED TO ATTRACT ANGEL INVESTORS, VENTURE CAPITAL, OR LICENSING BY AN INDUSTRY PARTNER. MOST FUND INVESTMENTS WILL LIKELY BE LESS THAN $100K DEPENDING ON THE TECHNOLOGY AND STAGE GATES PROPOSED TO ACHIEVE PROOF OF CONCEPT. THE LACK OF POC FUNDING WAS IDENTIFIED IN KCALSI'S PATH TO 2025 REPORT, CONFIRMING SIMILAR FINDINGS IN KCSOURCELINK'S WE CREATE CAPITAL ASSESSMENT OF REGIONAL CAPITAL AVAILABILITY. THE NEXUS POC FUND HELPS CLOSE A SIGNIFICANT GAP IN THE REGIONAL ENTREPRENEURIAL ECOSYSTEM. OUTCOMES RESEARCH AND HEALTH IT OUTCOMES RESEARCH AND HEALTH IT PRINCIPLES CAN BE APPLIED IN ALL ASPECTS OF HEALTH AND DISEASE MANAGEMENT. EXAMPLES OF ACTIVITIES PURSUED IN 2017 INCLUDE: -THE NEURODEVELOPMENT WORKING GROUP BEGAN CONSIDERING AN OUTCOMES/HEALTH IT RESEARCH APPROACH TO BETTER DEFINE AUTISM SPECTRAL DISORDERS (ASD) WITH MORE CONSISTENT DIAGNOSTICS TO STEER THE TREATMENT APPROACH THAT WORKS BEST IN CHILDREN WITH ASD. THIS IS A CLASSIC OUTCOMES RESEARCH PROBLEM WHERE VARIABLE DIAGNOSTICS AND TREATMENTS ARE CONFOUNDING OUTCOMES FOR CHILDREN WITH ASD. -THE OUTCOMES RESEARCH / HEALTH IT WORKING GROUP, LED BY DICK FLANIGAN, CERNER PRESIDENT, AND DR. JOHN SPERTUS, SAINT LUKE'S HEALTH SYSTEM, UMKC, DEVELOPED A VISION STATEMENT TO FRAME THEIR WORK STATING, "THE KANSAS CITY REGION IS DEVELOPING A VALUE-BASED COLLABORATIVE HEALTHCARE ECOSYSTEM TO ESTABLISH KANSAS CITY AS 'THE OUTCOMES RESEARCH REGION' IN THE NATION." OUTCOMES RESEARCH RECOGNIZES PATIENT VARIATION ACROSS A POPULATION AND IDENTIFIES INDIVIDUAL PATIENT RISKS. IT PROVIDES A PERSONALIZED MEDICINE APPROACH DELIVERING TO PHYSICIANS THE TOOLS AND DATA TO TREAT A PATIENT AS AN INDIVIDUAL, INSTEAD OF TREATING THEM AS A MEAN OF THE POPULATION. -TO CREATE THIS ECOSYSTEM, THE GROUP RECOGNIZED THE NEED TO ENGAGE A CRITICAL MASS OF REGIONAL HOSPITALS IN AN OUTCOMES PROJECT TO DEMONSTRATE THE OPPORTUNITY IN VALUE-BASED HEALTHCARE. KEY ELEMENTS WERE IDENTIFIED FOR DEVELOPING A SUCCESSFUL OUTCOMES PROJECT TO ASSESS POTENTIAL CANDIDATE PROJECTS. AFTER CONSIDERABLE DELIBERATIONS, THE WORKING GROUP SELECTED PERCUTANEOUS CORONARY INTERVENTION (PCI) USING THE E-PRISM TOOL DEVELOPED BY HEALTH OUTCOME SCIENCES. THE E-PRISM TOOL USES OVER 90 PARAMETERS FROM A PATIENT'S ELECTRONIC MEDICAL RECORD TO DETERMINE BLEEDING AND ACUTE KIDNEY INJURY (AKI) RISKS FOLLOWING THE PROCEDURE AND PROVIDES THIS INFORMATION TO THE INTERVENTIONAL CARDIOLOGIST TO CUSTOMIZE TREATMENT FOR EACH PATIENT. SIGNIFICANT SAVINGS TO THE HOSPITAL ARE REALIZED IN AVOIDING ADVERSE EVENTS - OVER $8,000 PER PATIENT FOR BLEEDING, OVER $10,000 FOR EACH AKI EVENT, AND OVER $100,000 PER PATIENT FOR KIDNEY DIALYSIS, NOT TO MENTION THE BENEFIT FOR THE PATIENT. AT BARNES JEWISH HOSPITAL IN ST LOUIS, BLEEDING RATES AND AKI RATES DECREASED FROM ABOUT 8-10% AT BASELINE TO 2% WITH THE E-PRISM TOOL. ADDITIONALLY, THE HOSPITAL SAVES OVER $3,500,000 ANNUALLY IN THIS SINGLE PROCEDURE. FORM 990, PART III, LINE 4A (CONTINUED) 2. COLLABORATE2CURE KCALSI CREATED THE COLLABORATE2CURE PROGRAM WITH THE GOAL OF STIMULATING REGIONAL SCIENTIFIC COLLABORATION AND DEVELOPING INNOVATIVE WAYS TO SOLVE SCIENTIFIC CHALLENGES. THE PROGRAM PROVIDES A PLATFORM FOR COLLABORATION, ALLOWING SCIENTISTS IN THE KC REGION TO SHARE THEIR RESEARCH AND ULTIMATELY COMPETE FOR FUNDING. KCALSI IDENTIFIES A TOPIC WITH SIGNIFICANT INTEREST TO RESEARCHERS WHICH ALIGNS WELL WITH REGIONAL EXPERTISE, AND THEN COORDINATES A SERIES OF PRESENTATIONS FROM RESEARCHERS OVER THE COURSE OF SEVERAL MONTHS. THE 2017 COLLABORATE2CURE SERIES FOCUSED ON "MITOCHONDRIAL DYSFUNCTION." SCIENTISTS, CLINICIANS, STUDENTS, AND ENTREPRENEURS GATHERED OVER 14 WEEKS TO SHARE AND GAIN KNOWLEDGE SURROUNDING MITOCHONDRIAL DYSFUNCTION. MITOCHONDRIA ARE THE ENERGY POWERHOUSE OF THE CELL AND ARE RESPONSIBLE FOR CREATING MORE THAN 90% OF THE ENERGY NEEDED BY THE BODY TO SUSTAIN LIFE AND SUPPORT ORGAN FUNCTIONS. DISEASES LINKED TO FAILING MITOCHONDRIA INCLUDE ALZHEIMER'S DISEASE, ALS, OBESITY, HEART DISEASE, AND NEUROLOGICAL DISEASES. THE MITOCHONDRIAL DYSFUNCTION SERIES WAS CO-CHAIRED BY DRS. ABDULBAKI "BAKI "AGBAS FROM KANSAS CITY UNIVERSITY AND RUSSELL SWERDLOW FROM THE UNIVERSITY OF KANSAS MEDICAL CENTER. AFTER THE SERIES, A REQUEST FOR PROPOSALS WAS RELEASED TO SUPPORT COLLABORATIVE, RESEARCH PROJECTS SPAWNED FROM THE SERIES. THE WINNING PROJECT RECEIVED $50,000 FOR ONE YEAR TO COMPLETE THE RESEARCH PROJECT. 3. WORKFORCE DEVELOPMENT WORKFORCE DEVELOPMENT WAS IDENTIFIED IN KCALSL'S PATH TO 2025 REPORT AS A SIGNIFICANT THREAT TO AND CRITICAL WEAKNESS IN THE REGIONAL LIFE SCIENCE CLUSTER. KC RISING, A CIVIC INITIATIVE UNDERWAY ACROSS THE KANSAS CITY COMMUNITY, ESTABLISHED A HUMAN CAPITAL WORK GROUP TO ADDRESS WORKFORCE DEVELOPMENT ISSUES. RECOGNIZING THE OPPORTUNITY TO LEVERAGE A PARALLEL EFFORT, KCALSI INTEGRATED ITS EFFORTS AND EXPERTISE WITH KC RISING TO DEVELOP A REGIONAL PLAN OF ACTION. 2017 ACTIVITIES IN SUPPORT OF WORKFORCE DEVELOPMENT INCLUDED THE FOLLOWING: -THE TALENT TO INDUSTRY EXCHANGE (TIE) CONCEPT WAS INTRODUCED TO IMPROVE LABOR SUPPLY IN KEY INDUSTRY SECTORS AND GROW THE WORKFORCE NECESSARY TO ATTRACT AND RETAIN COMPANIES IN THE KANSAS CITY REGION. ENGAGEMENT WITH LOCAL LIFE SCIENCE COMPANY LEADERS AND EDUCATIONAL INSTITUTIONS LAUNCHED IN 2016. THE LIFE SCIENCES TIE LABOR ANALYSIS WAS PUBLISHED IN FEBRUARY 2017. ONE OF THE KEY CHARGES WAS TO ESTABLISH A REGIONAL ADVISORY COUNCIL (RAC). MUCH LIKE A PLATFORM TECHNOLOGY, THE RAC CAN ASSESS A VARIETY OF WORKFORCE ISSUES AND IDENTIFY EDUCATION SOLUTIONS MORE RAPIDLY AND EFFICIENTLY, TO MEET INDUSTRY NEEDS. -BIOINFORMATICS WILL BE THE FIRST FOCUS AREA FOR THE RAC, AS THIS INDUSTRY SECTOR STRUGGLES TO ACQUIRE ADEQUATELY SKILLED WORKERS. WITH GUIDANCE FROM INDUSTRY, NEW CURRICULA WILL BE THE DELIVERABLE. -CONTRACT RESEARCH ORGANIZATIONS WILL BE THE SECOND FOCUS AREA. GIVEN THE EVER-CHANGING NATURE OF THEIR WORKFLOW, THIS INDUSTRY SECTOR IS RIPE FOR USING STACKABLE CREDENTIALS TO MEET TRAINING NEEDS. THESE SHORT-TERM CREDENTIALS CAN BE "STACKED," LEADING TO TWO AND FOUR-YEAR DEGREES. -THE EMERGING ENTREPRENEUR PROOF OF CONCEPT FUND (E2POC) PROGRAM HARVESTS ORPHAN TECHNOLOGIES DEVELOPED BY HIGH SCHOOL AND COLLEGE STUDENTS COMPETING IN REGIONAL STEM COMPETITIONS. TO INCREASE ENTREPRENEURS IN THE REGION, THE E2POC PROGRAM WILL ENGAGE STUDENT INVENTORS BY PROVIDING ENTREPRENEURSHIP RESOURCES, ASSISTING WITH BUSINESS PLAN DEVELOPMENT, ASSESSING MARKETS, INTELLECTUAL PROPERTY, AND ACCESSING CAPITAL. APPROXIMATELY 3 - 5 SUCCESSFUL APPLICANTS ANNUALLY WILL RECEIVE $5,000 SCHOLARSHIPS AND THE E2POC WILL FUND THE PROOF OF CONCEPT WORK AND PATENT PROSECUTION. THE ENTREPRENEUR WILL BE PAIRED WITH BUSINESS MENTORS TO AUGMENT THEIR ENTREPRENEURIAL EDUCATION. ADDITIONAL SCHOLARSHIPS WILL BE GRANTED, UP TO $20,000, AS THE PRODUCT MOVES TOWARD COMMERCIALIZATION. THE E2POC HAS TWO IMPORTANT OUTCOMES: (1) TRAIN YOUNG ENTREPRENEURS, AND (2) ADVANCE INNOVATIVE TECHNOLOGIES TO MARKET BY DIRECTLY FUNDING THE TECHNICAL STUDIES NECESSARY TO DE-RISK THEM TO ATTRACT INVESTORS. 4. KCALSI'S RESEARCH DEVELOPMENT GRANT PROGRAMS THE KCALSI RESEARCH DEVELOPMENT GRANTS PROGRAM REPRESENTS ONE OF OUR OLDEST AND MOST POPULAR PROGRAMS. GRANTS ARE AWARDED TO GENERATE PRELIMINARY DATA THAT SUPPORT SUBMISSION OF MAJOR MULTIDISCIPLINARY RESEARCH PROPOSALS TO GOVERNMENT OR PRIVATE FUNDING AGENCIES. APPLICANTS RECEIVE WRITTEN PEER REVIEWS, REGARDLESS OF WHETHER THEIR PROJECT RECEIVED FUNDING, TO HELP THEM IMPROVE FUTURE GRANT APPLICATIONS. THIS IS A VALUED SERVICE APPRECIATED BY ALL TEN STAKEHOLDERS. FROM 2007 TO 2017, KCALSI HAS MANAGED 77 GRANTS TOTALING $3.7 MILLION. ON AVERAGE, FOR EVERY $1 INVESTED IN GRANTS, $9.10 HAS BEEN RETURNED TO THE REGION FROM FOLLOW-ON FEDERAL SOURCES. IMPORTANTLY, THIS NUMBER SHOULD BE VIEWED CONSERVATIVELY AS NO INFORMATION IS READILY AVAILABLE REGARDING GRANTS MADE TO REGIONAL SCIENTISTS BY PRIVATE FOUNDATIONS AND PATIENT ADVOCACY ORGANIZATIONS. THE 2017 KCALSI RESEARCH DEVELOPMENT GRANT PORTFOLIO INCLUDES: BLUE KC OUTCOMES RESEARCH GRANTS FOCUS ON IMPROVING THE HEALTHCARE QUALITY, REDUCING COSTS, IMPROVING EFFECTIVENESS OR EFFICIENCY OF THE HEALTHCARE PROCESS, AND/OR IMPROVING ACCESS TO HEALTHCARE. PARTNERING WITH BLUE CROSS AND BLUE SHIELD OF KANSAS CITY, KCALSI AWARDED THREE GRANTS OF UP TO $50,000 EACH IN MAY 2016. THE GRANTS WERE PRESENTED TO THREE RESEARCH SCIENTISTS, TWO AT CHILDREN'S MERCY AND ONE AT THE UNIVERSITY OF KANSAS MEDICAL CENTER. PAUL PATTON CHARITABLE TRUST GRANTS FOCUS ON GENETIC DISEASES MAINLY AFFECTING CHILDREN. THE FUNDS FOR THIS PROGRAM ARE PROVIDED BY THE PAUL PATTON TRUST, TED C. MCCARTER, WILLIAM EVANS JR. AND BANK OF AMERICA, N.A., TRUSTEE. KCALSI AWARDED GRANTS OF UP TO $50,000 TO THREE RESEARCHERS, TWO AT CHILDREN'S MERCY, AND ONE AT THE UNIVERSITY OF MISSOURI. NEXUS OF HUMAN AND ANIMAL HEALTH GRANTS FOCUS ON BIOMEDICAL RESEARCH PROJECTS, RANGING FROM USING NATURALLY OCCURRING DISEASES IN ANIMALS AS A MODEL FOR ASSESSING HUMAN DRUG EFFICACY TO REPURPOSING HUMAN DRUGS FOR USE IN ANIMAL DISEASES. FUNDED BY THE HALL FAMILY FOUNDATION, KCALSI AWARDED $50,000 GRANTS EACH TO FIVE RESEARCHERS, THREE AT KANSAS STATE UNIVERSITY, ONE AT THE UNIVERSITY OF MISSOURI, AND ONE AT THE UNIVERSITY OF KANSAS. COLLABORATE2CURE GRANTS ARE SPECIFICALLY USED TO SUPPORT NEW COLLABORATIONS AND INNOVATIVE APPROACHES TO SOLVING PROBLEMS SPAWNED FROM THE COLLABORATE2CURE PROGRAM SERIES. KCALSI AWARDED TWO $50,000 GRANTS EACH TO RESEARCHERS AT THE UNIVERSITY OF MISSOURI AND KANSAS CITY UNIVERSITY. 5. 2017 ANNUAL DINNER AND "SCIENCE TO ART" AUCTION CLOSE TO 500 COMMUNITY LEADERS, SCIENTIFIC LEADERS, AND COLLEGE AND HIGH SCHOOL STUDENTS ATTENDED THE SEPTEMBER 19, 2017 KCALSI ANNUAL DINNER. NINA TANDON, FOUNDER AND CEO OF EPIBONE, PROVIDED THE CAPTIVATING KEYNOTE PRESENTATION EMPHASIZING SEVERAL WAYS THE AUDIENCE COULD HELP ADVANCE OUR FUTURE. HER PRESENTATION PROVIDED EXAMPLES OF INNOVATIVE APPROACHES TO TISSUE ENGINEERING. "IT'S VERY EXCITING BECAUSE WHAT WE'RE DOING IS CONNECTING WITH WHAT THE BODY DOES NATURALLY," SHE SAID. DR. TANDON URGED THE AUDIENCE TO LEVERAGE THE UNIQUE STRENGTHS OF THIS REGION, E.G., THE ANIMAL HEALTH CORRIDOR, CONCENTRATION OF CONTRACT RESEARCH ORGANIZATIONS (CROS), ETC. SHE FURTHER ENCOURAGED THE REGION TO FOSTER A RICH LIFE SCIENCES ECOSYSTEM, AND TO IDENTIFY PATHWAYS BRIDGING THE VENTURE CAPITAL FUNDING GAP. SHE CLOSED HER PRESENTATION BY REMINDING US THAT SCIENTIFIC ETHICS ARE CRUCIAL TO ADVANCE OUR FUTURE. DR. WAYNE CARTER, KCALSI PRESIDENT AND CEO, PROVIDED A PERSPECTIVE ON THE NEXUS OF HUMAN AND ANIMAL MEDICINE BY HIGHLIGHTING REGIONAL COMPANIES THAT ARE ADVANCING OUR FUTURE WITH NEW THERAPIES FOR PEOPLE AND DOGS, AND EXECUTION ON THE PATH TO 2025 STRATEGY. DR. CARTER CONCLUDED WITH A CALL-TO-ACTION TO ADVANCE OUR FUTURE, ENCOURAGING THE AUDIENCE TO: (1) CONTINUE TO COLLABORATE (2) MENTOR HIGH SCHOOL AND EARLY COLLEGE STUDENTS, AND (3) INVEST IN REGIONAL FUNDING PROGRAMS AND STARTUP COMPANIES. THIS WAS THE FOURTH CONSECUTIVE YEAR FOR KCALSI'S SCIENCE TO ART SILENT AUCTION HELD DURING OUR ANNUAL DINNER. BIDDING WAS AVAILABLE TO THE PUBLIC THROUGH THE KCALSI WEBSITE DURING THE SIX-WEEK EXHIBITION OF THE ARTWORK AT KEMPER AT THE CROSSROADS. THE KEMPER MUSEUM OF CONTEMPORARY ART WAS AN INSTRUMENTAL PARTNER FOR THIS EXHIBIT. THIS YEAR'S AUCTION PROCEEDS OF OVER $10,000 WERE MADE AVAILABLE FOR STEAM EDUCATION, SPECIFICALLY BIOGENEIUS, PREP-KC, SCIENCE CITY AND THE GREATER KANSAS CITY SCIENCE & ENGINEERING FAIR, AND FREE EDUCATIONAL PROGRAMS AT THE KEMPER MUSEUM. FORM 990, PART III, LINE 4A (CONTINUED) 6. ONE HEALTH INNOVATIONS SYMPOSIUM THE 2017 ONE HEALTH INNOVATIONS: PREVENTING THE NEXT PANDEMIC SYMPOSIUM WAS HELD AUGUST 27-28 AT THE KANSAS CITY CONVENTION CENTER. KCALSI COORDINATED THIS TWO-DAY EVENT ALONG WITH THE UNIVERSITY OF MISSOURI, KANSAS STATE UNIVERSITY AND INDUSTRY PARTNERS. THE SYMPOSIUM FEATURED OVER 20 NATIONAL AND REGIONAL EXPERTS ADDRESSING THIS TOPIC FROM TWO PERSPECTIVES: (1) HOW CAN SURVEILLANCE DATA, SOCIAL TRAFFICKING, AND BIG DATA BE USED TO IDENTIFY POTENTIAL OUTBREAKS EARLIER, TO FACILITATE RAPID RESPONSE, AND (2) WHAT ARE THE LATEST VACCINE PLATFORMS BEING APPLIED TO VIRAL AND EMERGING DISEASES INCLUDING A SEGMENT ON NOVEL TREATMENT APPROACHES. THE SYMPOSIUM FEATURED THREE KEYNOTE PRESENTERS, DR. GREG GRAY, DUKE UNIVERSITY, "ONE HEALTH: AN INCREASINGLY POPULAR APPROACH TO WICKED GLOBAL HEALTH PROBLEMS," DR. MARK CHALLBERG, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES WHO DISCUSSED, "ZIKA VACCINE DEVELOPMENT: STARTING FROM SCRATCH, AND DR. MARTY VANIER, WITH THE NATIONAL BIO AND AGRO-DEFENSE FACILITY WHO PRESENTED ON "NATIONAL BIO AND AGRO-DEFENSE FACILITY: A NEW PARADIGM. HIGHLIGHTS OF DAY 1 INCLUDED DR. TRACEY MCNAMARA WHO FIRST IDENTIFIED WEST NILE VIRUS IN THE UNITED STATES, AND DR. JORGE SOBERON WHO DISCUSSED DISEASE SPREAD USING ECOLOGY AND EVOLUTIONARY BIOLOGY. DAY 2 INCLUDED PRESENTATIONS BY DR. SCOTT MCVEY FEATURING FAST-TRACK APPROACHES FOR EMERGING DISEASES AND DR. SAMUEL THEVASAGAYAM FROM THE GATES FOUNDATION FOCUSED ON CHALLENGES OF SUB-SAHARAN AFRICA VACCINE MANUFACTURING. 7. ONE HEALTH DAY THE ONE HEALTH CONCEPT LEVERAGES MULTIPLE DISCIPLINES WORKING LOCALLY, NATIONALLY AND GLOBALLY LINKING HUMAN HEALTH, ANIMAL HEALTH, AND THE ENVIRONMENT. KCALSI PARTNERED WITH KANSAS STATE UNIVERSITY AND BIOKANSAS TO HOST "KANSAS CITY ONE HEALTH DAY." DR. CARTER PROVIDED AN OVERVIEW OF ONE HEALTH. HE NOTED THAT A FOCUSED RESEARCH APPROACH IS IMPORTANT, HOWEVER, BEING ABLE TO SEE THE BIG PICTURE RELATING TO INTERDISCIPLINARY DATA IS CRITICAL. PANELISTS INCLUDED, DR. BARBARA BICHELMEYER, INTERIM CHANCELLOR, UMKC, DR. TOM CURRAN, CHIEF SCIENTIFIC OFFICER, CHILDREN'S MERCY, KELLY RANALLO, FOUNDER, RAREKC, DENNIS RIDENOUR, PRESIDENT AND CEO OF BIOKANSAS, DR. LAURA TREML, VP OF DRUG DEVELOPMENT, ARATANA, AND DR. RAELENE WOUDA, ASSISTANT PROFESSOR, K-STATE COLLEGE OF VETERINARY MEDICINE. THEY EMPHASIZED THE NEED TO MOVE OUT OF DISCIPLINARY SILOS TO ADVANCE ONE HEALTH. TAKING THIS APPROACH POSITIONS HUMAN, ANIMAL, AND ENVIRONMENTAL RESEARCH AS CRUCIAL ELEMENTS CONTRIBUTING TO FINDING NEW CURES. 8. BIOINFORMATICS 1. IN 2017, KCALSI CREATED A TOOL FOR THE REGION TO ORGANIZE BIOINFORMATICS ASSETS SUPPORTING HUMAN AND ANIMAL HEALTH RESEARCH. THIS WEBSITE INCLUDES CAPABILITIES AND RESEARCH EXPERTISE TO FACILITATE COLLABORATIVE RESEARCH. WWW.KCBIOINFORMATICS.ORG 2. IN PARTNERSHIP WITH CHILDREN'S MERCY AND UMKC, KCALSI PRESENTED THE SECOND ANNUAL MIDWEST BIOINFORMATICS CONFERENCE ON APRIL 13 -14, 2017 FEATURING 30 SPEAKERS SHOWCASING PRACTICAL APPROACHES TO COLLECTING, ORGANIZING, AND PREPARING DATA FOR A BROAD RANGE OF ANALYSES APPLIED IN HUMAN AND ANIMAL HEALTH. THE CONFERENCE WAS HOSTED ON THE UMKC CAMPUS AND CONVENED NEARLY 200 BIOINFORMATICS-MINDED RESEARCHERS FROM ACADEMIA AND INDUSTRY TO DISCOVER CAPABILITIES, SHARE TACTICAL APPROACHES TO PROBLEM-SOLVING, EXPLORE SYNERGIES, AND LAUNCH POTENTIAL COLLABORATIONS. ADDITIONALLY, BIOINFORMATICS STUDENTS LEARNED ABOUT EMPLOYMENT OPPORTUNITIES WITHIN THE REGION AND PARTICIPATED IN MOCK INTERVIEWS. INTRODUCED THIS YEAR, A SUBSET OF 29 STUDENT POSTERS WAS CONSIDERED FOR PODIUM PRESENTATIONS, WITH FOUR STUDENTS SELECTED FOR THIS HONOR. 9. W.I.S.E KC KCALSI REALIZES THAT EMPOWERING WOMEN AND ADVOCACY FOR WOMEN IN SCIENCE AND ENTREPRENEURSHIP (W.I.S.E.) IS CRUCIAL FOR DEVELOPING THE NEXT GENERATION OF WOMEN IN STEM. KCALSI ORGANIZED THE W.I.S.E. KC" EVENT IN PARTNERSHIP WITH BIOKANSAS, MISSOURI CURES, AND THE MISSOURI BIOTECHNOLOGY ASSOCIATION. THE EVENT INCLUDED A PANEL WITH FOUR FEMALE ENTREPRENEURS: ELIZABETH LOBOA, DEAN OF THE COLLEGE OF ENGINEERING AT THE UNIVERSITY OF MISSOURI, REBECCA MACKINNON, PRINCIPAL AND FOUNDER OF 5TH DIMENSION STRATEGIES, TAMMIE WAHAUS, CEO OF ELIAS ANIMAL HEALTH, AND NANCY ZURBUCHEN, SMALL BUSINESS ADVOCATE, REGION 7, SMALL BUSINESS ADMINISTRATION. THE PANELISTS SHARED CAREER EXPERIENCES WITH OVER 200 ATTENDEES AT THE KAUFFMAN FOUNDATION. DEAN LOBOA FOCUSED ON LOW ENROLLMENT, AND GRADUATION STATISTICS ABOUT FEMALE ENGINEERING STUDENTS LOCALLY AND NATIONALLY. THE PANELISTS ENCOURAGED TAKING ACTION TO INCREASE WOMEN IN STEM CAREERS. LOBOA IS LEADING BY EXAMPLE AND DEMANDING CHANGE FROM HER PEERS. THE CHALLENGE IS TO BE MORE THAN A MENTOR, BE A SPONSOR BY HELPING TO IDENTIFY, PROMOTE, AND ADVOCATE FOR WOMEN WITHIN YOUR ORGANIZATIONS. INCREASING WOMEN IN SCIENCE INCREASES THE SUCCESS OF STEM COMPANIES. FORM 990, PART VI, SECTION A, LINE 2 ANNE D. ST. PETER AND STEVEN ST. PETER,MD HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION HAS A POLICY FOR THE ORGANIZATION'S AUDIT COMMITTEE TO REVIEW THE 990 BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C ALL STAFF AND DIRECTORS MUST SUBMIT ANY CONFLICTS OF INTEREST ON AN ANNUAL BASIS. IF A CONFLICT ARISES WITHIN THE BOARD, THE DISCLOSING INDIVIDUAL SHALL NEITHER VOTE NOR ENDEAVOR TO INFLUENCE THE DECISION. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION OF THE ORGANIZATION'S PRESIDENT IS AGREED UPON BY THE BOARD OF DIRECTORS AND FINALIZED VIA A WRITTEN EMPLOYMENT CONTRACT. THIS APPROVAL IS DOCUMENTED IN THE MINUTES OF THE BOARD. IN 2013 THE ORGANIZATION CREATED A COMPENSATION COMMITTEE AND CONDUCTED A COMPENSATION STUDY TO FURTHER REFINE THE COMPENSATION PROCESS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE ONLY AVAILABLE UPON REQUEST. KC BIO HOLDINGS INC 30 W PERSHING ROAD STE 210 KANSAS CITY MO 64108 412115941 LIFE SCIENCES MO N/A C 1.00000 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0